ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01182025
Recruitment Status : Unknown
Verified August 2010 by The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine.
Recruitment status was:  Recruiting
First Posted : August 16, 2010
Last Update Posted : August 17, 2010
Sponsor:
Collaborators:
Beijing University of Chinese Medicine
China Academy of Chinese Medical Sciences
Information provided by:
The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The aim of this study is to evaluate the effectiveness and safety of Xiyanping Injection for mild type of hand, foot, and mouth disease.

Condition or disease Intervention/treatment Phase
Hand, Foot and Mouth Disease Other: Western therapy Drug: Xiyanping Injection Drug: Xiyanping Injection with western medicine Not Applicable

Detailed Description:
By adopting a multi-center, randomized and controlled clinical trial, this study is aimed to evaluate the efficacy and safety of Xiyanping Injection in the treatment of mild type of Hand, Foot and Mouth Disease (HFMD), and designed to combine both observational and interventional methodologies in this research.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 360 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : June 2010
Estimated Primary Completion Date : May 2011
Estimated Study Completion Date : December 2011

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Western therapy Other: Western therapy

Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.

  1. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;
  2. Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;
Experimental: Xiyanping Injection Drug: Xiyanping Injection

Dosage for child medication:

5-10mg/kg/d (0.2-0.4ml/kg/d) in 5% Glucose solution, IV, with speed of 20-30 drops per minute, each day; or as directed by doctor.
Experimental: Xiyanping Injection with western medicine Drug: Xiyanping Injection with western medicine
  1. Symptomatic treatment using the same treatment methods in western therapy group;
  2. Symptomatic treatment using the same treatment methods in Xiyanpin injection group.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. time of bringing down the fever [ Time Frame: 10 days ]
    Refering to the length of time to bring down the fever by 0.5 degrees Celsius after the medicine is taken.

  2. time of body temperature going back to normal [ Time Frame: 10 days ]
    Refering to the time of the armpit temperature of lower than 37.0 degrees Celsius, lasting for at least 24 hours, after the medicine is taken.


Secondary Outcome Measures :
  1. time of symptom disappearance [ Time Frame: 10 days ]
    Refering to the length of time when clinical symptoms and signs totally disappere after the medicine is used.

  2. case severity rate [ Time Frame: 10 days ]
    Refering to the ratio of patient with mild type of HFMD to severe type, such as damage of central nervous system, pulmonary edema, heart failure, respiratory failure, etc.

  3. time of tetter disappearance [ Time Frame: 10 days ]
    Refering to the length of time when the tetter due to HFMD disappears, characterised by scab(s) or dropping; and time of oral ulcer concrescence, etc.

  4. direct medical cost [ Time Frame: 10 days ]
    Referring to the costs in the treatment of HFMD and relative disease, including the registration fee, examination fee, and drug fees, etc.

  5. safety outcome [ Time Frame: 10 days ]
    Calculated by adverse event.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Year to 14 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of severe hand-foot-mouth disease patients according to Hand-Foot-Mouth Disease Treatment Guidelines 2010 issued by China's Ministry of Health; More than 1/3 patients should be diagnosed by etiological examination.
  • Less than 48 hours of occurrence of fever and/or occurrence of tetter or herpes.
  • Age of 1-14 years.
  • Patients or their guardians agree to participate in this study and signed the informed consent form.

Exclusion Criteria:

  • Complicated with other serious primary diseases in organ such as congenital heart disease, chronic hepatitis, nephritis and blood diseases, etc.
  • With history of allergies on traditional Chinese medicine.
  • Patients or their guardians suffering from Psychiatric diseases.
  • Attending other clinical studies on HFMD after diagnosed.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01182025


Locations
China, Guangxi
Affiliated Hospital of Guilin Medical College Recruiting
Guilin, Guangxi, China, 541001
Contact: Xiong Li    13737728526    yuanyanhui_888@163.com   
Principal Investigator: Xiong Li         
Liuzhou Worker's Hospital Recruiting
Liuzhou, Guangxi, China, 541001
Contact: Liuping Tang    18977228768    yongren126zeng@126.com   
Contact: Zhe Guo    13978009767    sdy761212@163.com   
Principal Investigator: Liuping Tang         
Principal Investigator: Zhe Guo         
Liuzhou People's Hospital Recruiting
Liuzhou, Guangxi, China, 545001
Contact: Tong Yang    13977286628    zhoubing-1995@163.com   
Principal Investigator: Tong Yang         
China, Guangzhou
Shenzhen Maternity & Child Healthcare Hospital Recruiting
Shenzhen, Guangzhou, China, 518028
Contact: Xinying Zou    13129559135    Xuzhiymr@yahoo.com.cn   
Principal Investigator: Xinying Zou         
China, Jiangxi
Jiangxi Provincial Children's Hospital Recruiting
Nanchang, Jiangxi, China, 330006
Contact: Qingxiong Zhu    15979003000    Zhuqingxiong2000@163.com   
Principal Investigator: Qingxiong Zhu         
Sponsors and Collaborators
The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Beijing University of Chinese Medicine
China Academy of Chinese Medical Sciences
Investigators
Principal Investigator: Guoliang Zhang An'Hui Chinese Medical College Affiliated No.1 Hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Guoliang Zhang, The First Affiliated Hospital of Anhui College of Traditional Chinese Medicine
ClinicalTrials.gov Identifier: NCT01182025     History of Changes
Other Study ID Numbers: 200907001-4
First Posted: August 16, 2010    Key Record Dates
Last Update Posted: August 17, 2010
Last Verified: August 2010

Keywords provided by The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine:
Mild type of hand, foot and mouth disease
Xiyanping Injection
Effectiveness
Safety

Additional relevant MeSH terms:
Mouth Diseases
Foot-and-Mouth Disease
Hand, Foot and Mouth Disease
Stomatognathic Diseases
Picornaviridae Infections
 RNA Virus Infections
Virus Diseases
Coxsackievirus Infections
Enterovirus Infections